文献速递胸部肿瘤

英国一线晚期非小细胞肺癌患者中前置游离DNA二代测序改善靶点识别

Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
PubMed 文献 · Eur J Cancer · 2022-06-12

该研究纳入2019年12月至2021年10月连续新诊断的311例晚期非小细胞肺癌患者,同期进行cfDNA-NGS与常规组织基因分型。cfDNA-NGS在282例(91%)中获信息性结果,118例(38%)检出 tier-1 变异;配对检测中cfDNA-NGS较组织检测多检出39个 tier-1 变异,将 tier-1 检出率从85例提高至124例(提高46%),且报告时间与治疗启动时间均缩短。作者认为应常规考虑前置cfDNA-NGS。

要点

  • 311例晚期NSCLC中282例(91%)cfDNA-NGS获信息性结果,118例(38%)检出 tier-1 变异。
  • 配对检测中cfDNA-NGS较组织多检出39个 tier-1 变异,检出率由85例增至124例(提高46%)。
  • cfDNA-NGS报告中位时间8天 vs 组织22天,采样至一线治疗启动中位16天 vs 35天。

核心结论

  • cfDNA-NGS提高了 tier-1 变异检出率,与组织检测高度一致,并将至治疗时间减半。
  • 作者认为晚期NSCLC应常规考虑前置「血浆优先」cfDNA-NGS。

研究设计与样本

  • 研究为在2019年12月至2021年10月连续纳入新诊断晚期NSCLC患者,同期进行cfDNA-NGS与常规组织基因分型的前瞻性对比研究。
  • 共纳入311例患者,其中243例有配对的组织-cfDNA检测结果。
  • 变异解读采用AMP/ASCO/CAP指南,主要终点为cfDNA-NGS检出的 tier-1 变异。

主要发现

  • 311例中282例(91%)cfDNA-NGS为信息性结果,118例(38%)检出 tier-1 变异。
  • 243例配对检测中组织检测信息性122例(50%),检出 tier-1 变异85例(35%)。
  • cfDNA-NGS较组织单独检测多检出39个 tier-1 变异,检出率提高46%(从85例增至124例)。
  • cfDNA-NGS相对组织的敏感性为75%,25%的组织 tier-1 变异未被cfDNA-NGS检出;33%的cfDNA tier-1 变异未被组织检测检出。
  • cfDNA-NGS从申请至报告中位时间8天 vs 组织22天(p < 0.0001);采样至一线治疗启动中位时间16天 vs 首次组织活检35天(p < 0.0001)。

关键数值与推荐

  • 311例中245例(79%)接受一线系统治疗,其中49例(20%)仅依据cfDNA-NGS结果。
  • cfDNA-NGS相对组织的敏感性为75%,25%的组织 tier-1 变异未被cfDNA-NGS检出。
  • 33%的cfDNA tier-1 变异未被组织检测检出。
  • cfDNA-NGS报告中位时间8天 vs 组织22天(p < 0.0001)。
  • 采样至一线治疗启动中位时间cfDNA采血16天 vs 首次组织活检35天(p < 0.0001)。

临床怎么用

  • 作者认为晚期NSCLC应常规考虑前置「血浆优先」cfDNA-NGS。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation sequencing (NGS) is standard but tissue quantity, quality, and time-to-results remains problematic. Here, we compare upfront cell-free-DNA (cfDNA) NGS clinical utility against routine tissue testing in patients with aNSCLC. METHODS: cfDNA-NGS was performed in consecutive, newly identified aNSCLC patients between December 2019-October 2021 alongside routine tissue genotyping. Variants were interpreted using AMP/ASCO/CAP guidelines. The primary endpoint was tier-1 variants detected on cfDNA-NGS. cfDNA-NGS results were compared to tissue results. RESULTS: Of 311 patients, 282 (91%) had an informative cfDNA-NGS test; 118 (38%) patients had a tier-1 variant identified by cfDNA-NGS. Of 243 patients with paired tissue-cfDNA tests, 122 (50%) tissue tests were informative; 85 (35%) tissue tests identified a tier-1 variant. cfDNA-NGS detected 39 additional tier-1 variants compared to tissue alone, increasing the tier-1 detection rate by 46% (from 85 to 124). The sensitivity of cfDNA-NGS relative to tissue was 75% (25% tissue tier-1 variants were not detected on cfDNA-NGS); 33% of cfDNA tier-1 variants were not identified on tissue tests. Median time from request-to-report was shorter for cfDNA-NGS versus tissue (8 versus 22 days; p < 0.0001). A total of 245 (79%) patients received first-line systemic-therapy: 49 (20%) with cfDNA-NGS results alone. Median time from sampling-to-commencement of first-line treatment was shorter for cfDNA-NGS blood draw versus first tissue biopsy (16 versus 35 days; p < 0.0001). CONCLUSIONS: cfDNA-NGS increased the tier-1 variant detection rate with high concordance with tissue, and halves time-to-treatment. 'Plasma-first' upfront cfDNA-NGS use should be considered routinely for aNSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022. PMID: 35704974. doi:10.1016/j.ejca.2022.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。